Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
|Videos|March 9, 2015
Improving the Relationship Between Manufacturers and Specialty Pharmacies
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses streamlining contractual relationships between specialty stakeholders and drug manufacturers.
Advertisement
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses streamlining contractual relationships between specialty stakeholders and drug manufacturers.
Advertisement
Related to this article
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
3
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
4
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
5